首頁 > 市場調查報告書 > 製藥

非專利藥生技仿製藥

市場調查報告書

商品編碼

1741193

Humira生物相似藥市場：依產品類型、適應症、通路、病患年齡及地區分類

Humira Biosimilar Market, By Product Type, By Indication, By Distribution Channel, By Patient Age, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 155 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2025 年， Humira生物相似藥市場規模估計為 15.405 億美元，預計到 2032 年將達到 77.24 億美元，2025 年至 2032 年的年複合成長率為 25.9%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	15.405億美元
效能數據	2020-2024	預測期	2025-2032
預測期間：2025年至2032年的年複合成長率	25.90%	2032年價值預測	77.24億美元

Humira）是生技藥品用於治療乾癬和類風濕性關節炎等自體免疫疾病的生物製劑，是世界上最受歡迎的生技藥品。在某些地區，Humira的專利保護到期後，生物相似藥在安全性、有效性和品質方面與生技藥品高度相似。這些生物相似藥可以促進競爭並降低價格。生物相似藥可以透過提供更經濟的治療選擇來幫助降低成本並改善患者獲得基本藥物的途徑。生物相似藥已被證明與原廠生技藥品一樣有效和安全，使其成為乾癬和類風濕性關節炎等疾病患者的可行選擇。此外，生物相似藥的可用性刺激了製藥業的創新，鼓勵製造商在不影響品質的情況下開發更實惠的治療方案。這種市場競爭可以降低價格並提高患者的可近性，最終改善醫療保健結果。此外，生物相似藥的引入還可以增加患者的選擇和自主權，使患者能夠根據自己的特定需求選擇最具成本效益的治療方法。

市場動態

專利到期、成本降低、自體免疫疾病盛行率增加以及有利的法規環境是預計在預測期內推動全球Humira生物相似藥市場成長的關鍵因素。

例如，北美已有多個修美樂（Humira）生物相似藥核准和許可，引領生物相似藥的推廣市場。該地區擁有支持生物相似藥推廣的法律體制和政策，這將增強市場競爭並帶來潛在的成本節約。

然而，複雜的監管流程、智慧財產權和專利訴訟以及醫生和患者的意識預計將在預測期內阻礙全球腦血管造影市場的成長。

研究的主要特點

本報告對全球Humira生物相似藥市場進行了詳細分析，並以 2024 年為基準年，展示了預測期 2025-2032 的市場規模和年複合成長率。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
該報告根據公司亮點、產品系列、關鍵亮點、財務表現和策略等參數，概述了全球Humira生物相似藥市場的主要企業。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、高階市場策略、市場擴張和行銷策略做出明智的決策。
全球Humira生物相似藥市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
相關人員將透過全球Humira生物相似藥市場分析中使用的各種策略矩陣更輕鬆地做出決策。

介紹
北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 東南亞國協
- 澳洲
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
中東
- 海灣合作理事會國家
- 以色列
- 其他中東地區
非洲
- 北非
- 中部非洲
- 南非

第10章競爭格局

公司簡介
- Amgen Inc.
- Samsung Bioepis Co.
- Sandoz International GmbH（Novartis AG）
- Mylan NV
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences
- Biogen Inc
- AbbVie Inc
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co
- Viatris Inc.
- Alvotech
- Analysts'Views

第 11 章章節

參考
調查方法
關於出版商

簡介目錄

Product Code: CMI5925

Humira Biosimilar Market is estimated to be valued at USD 1,540.5 Mn in 2025 and is expected to reach USD 7,724.0 Mn by 2032, growing at a compound annual growth rate (CAGR) of 25.9% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 1,540.5 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	25.90%	2032 Value Projection:	USD 7,724.0 Mn

Humira is a biologic medication used to treat autoimmune conditions like psoriasis and rheumatoid arthritis and is the most popular biologic medication in the world. Following the expiration of patent protection for humira in some regions, biosimilars are highly similar copies of biologic medications in terms of safety, efficacy, and quality. These biosimilars encourage competition and may result in price reductions. They help lower costs and improve patient access to essential pharmaceuticals by offering more economical treatment options. Biosimilars have been proven to be just as effective and safe as the original biologic medications, making them a viable alternative for patients with conditions like psoriasis and rheumatoid arthritis. Additionally, the availability of biosimilars promotes innovation in the pharmaceutical industry, as it encourages manufacturers to develop more affordable treatment options without compromising quality. This competition in the market can drive down prices and increase accessibility for patients, ultimately leading to improved healthcare outcomes. Furthermore, the introduction of biosimilars can also enhance patient choice and autonomy, allowing them to select the most suitable and cost-effective treatment for their specific needs.

Market Dynamics

Patent expiration, cost savings, increasing prevalence of autoimmune diseases, favorable regulatory environment is major factors expected to drive growth of the global humira biosimilar market during the forecast period.

For instance, the market for multiple humira biosimilars has been approved and introduced in North America, which has led the way in the adoption of biosimilars. Due to the region's existing legal framework and policies supporting biosimilar adoption, there will likely be more market competition and potential cost reductions.

However, complex regulatory processes, intellectual property and patent litigation, and physician and patient awareness are expected to hamper the growth of the global cerebral angiography market over the forecast period.

Key features of the study:

This report provides in-depth analysis of the global humira biosimilar market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global humira biosimilar market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Samsung Bioepis Co., Ltd., Sandoz International GmbH (Novartis AG), Mylan N.V., Boehringer Ingelheim International GmbH, Pfizer Inc., Fresenius Kabi AG, Coherus BioSciences, Inc., Biogen Inc., AbbVie Inc., Celltrion Inc., Rani Therapeutics Holdings, Inc., Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., Viatris Inc., and Alvotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global humira biosimilar market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global humira biosimilar market

Humira Biosimilar Market Detailed Segmentation:

By Product Type:
- Biosimilar Humira (Adalimumab)
- Interchangeable Biosimilar Humira
By Indication:
- Rheumatoid Arthritis
- Psoriasis
- Crohn's Disease
- Ulcerative Colitis
- Ankylosing Spondylitis
- Juvenile Idiopathic Arthritis
- Other Autoimmune Conditions
By Patient Age:
- Adult Patients
- Pediatric Patients
- Geriatric Patients
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Company Profiles:
- Amgen
- Samsung Bioepis Co., Ltd.
- Sandoz International GmbH (Novartis AG)
- Mylan N.V.
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Fresenius Kabi AG
- Coherus BioSciences, Inc.
- Biogen Inc.
- AbbVie Inc.
- Celltrion Inc.
- Rani Therapeutics Holdings, Inc.
- Teva Pharmaceutical Industries Ltd
- Merck & Co., Inc.
- Viatris Inc.
- Alvotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Patient Age
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Patent expiration
- Cost savings
- Increasing prevalence of autoimmune diseases
- Favorable regulatory environment
Market Restraints
Market Opportunity
Key Highlights
Regulatory Scenario
Recent Trends
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Mergers Acquisitions, and Collaborations

4. Global Humira Biosimilar Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Humira Biosimilar Market, By Product Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Biosimilar Humira (Adalimumab)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Interchangeable Biosimilar Humira
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Global Humira Biosimilar Market, By Indication, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Rheumatoid Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Crohn's disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Ulcerative Colitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Ankylosing Spondylitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Juvenile Idiopathic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Other Autoimmune Conditions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Global Humira Biosimilar Market, By Patient Age, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Geriatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Global Humira Biosimilar Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

9. Global Humira Biosimilar Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Patient Age, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/ Region, 2020-2032, (US$ Mn)
  - North Africa
  - Central Africa
  - South Africa

10. Competitive Landscape

Company Profiles
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Key Developments
  - Financial Performance
  - Strategies
- Samsung Bioepis Co.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Sandoz International GmbH (Novartis AG)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Fresenius Kabi AG
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Coherus BioSciences
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Biogen Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- AbbVie Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Celltrion Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Rani Therapeutics Holdings, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Merck & Co
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Viatris Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Alvotech
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Strategies
- Analysts' Views